NCCN Guidelines® Insights - Thyroid Carcinoma, Version 2.2018

The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E–mutated anaplastic thyroid carcinoma.

Target Audience

This activity is designed to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Integrate into professional practice the updates to the NCCN Guidelines for Thyroid Carcinoma
  • Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Thyroid Carcinoma
Additional information
Supporters: 

This activity is supported by educational grants from AstraZeneca, Celldex Therapeutics, Celgene Corporation, Genentech, Jazz Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, and Seattle Genetics, Inc. This activity is supported by independent educational grants from AbbVie, Merck & Co., Inc. and NOVOCURE.

Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
12/10/2018
Course expires: 
12/10/2019
Cost:
$0.00

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The NCCN staff listed below discloses no relevant financial relationships:
Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Emberger Hartzman, MA; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kanefield; and Kathy Smith.

INDIVIDUALS WHO PROVIDED CONTENT DEVELOPMENT AND/OR AUTHORSHIP ASSISTANCE:
Robert I. Haddad, MD, Panel Chair, has disclosed that he receives grant/research support from Merck & Co., Inc., Bristol-Myers Squibb Company, Genentech, Inc., and Pfizer Inc. He also receives consulting fees/honoraria from Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Celgene Corporation, Eisai Inc., AstraZeneca Pharmaceuticals LP, and Loxo Oncology, Inc.
Christian Nasr, MD, Panel Vice Chair, has disclosed that he receives consulting fees from Eisai Inc., Exelixis Inc., and Nevro Corp.; and that he receives honoraria from Shire plc and sanofi-aventis U.S. LLC.
Lindsay Bischoff, MD, Panel Member, has disclosed that she has no relevant financial relationships.
Hormoz Ehya, MD, Panel Member, has disclosed that he has no relevant financial relationships.
Whitney Goldner, MD, Panel Member, has disclosed that she has an other financial benefit from AstraZeneca Pharmaceuticals LP, Eisai Inc., and Roche Laboratories, Inc.
Megan Haymart, MD, Panel Member, has disclosed that she has no relevant financial relationships.
Peter Kopp, MD, Panel Member, has disclosed that he has no relevant financial relationships.
Rebecca Sippel, MD, Panel Member, has disclosed that she has no relevant financial relationships.
Cord Sturgeon, MD, Panel Member, has disclosed that he has no relevant financial relationships.
Lori J. Wirth, MD, Panel Member, has disclosed that she serves as a scientific advisor for Ayala Pharmaceuticals, Inc.; Bayer Healthcare; Eisai Inc.; Loxo Oncology, Inc.; and Merck & Co., Inc.
Richard Wong, MD, Panel Member, has disclosed that he has no relevant financial relationships.
Alyse Johnson-Chilla, MS, Guidelines Coordinator, NCCN, has disclosed that she has no relevant financial relationships.
Karin G. Hoffmann, RN, CCM, Guidelines Coordinator, NCCN, has disclosed that she has no relevant financial relationships [employed by NCCN until 6/1/18].
Lisa A. Gurski, PhD, Oncology Scientist/Medical Writer, NCCN, has disclosed that she has no relevant financial relationships.

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Physicians
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NCCN designates this journal-based CE activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: 0836-0000-18-012-H01-P

All clinicians completing this activity will be issued a certificate of participation.

Available Credit

  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing